Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Argipressin injection		Hospital use only
Arsenic trioxide	TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia	Hospital use only
Articaine 40mg in 1ml adrenaline injection		For dental use only
Asfotase alfa		NHSE commissioned
Asparaginase 10,000 units injection (5 vials)
Aspirin suppositories
Atezolizumab (Tecentriq®)	TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	Hospital use only
Atomoxetine		ESCAs and additional advice in relation to age of patient and CCG
Atosiban (Tractocile)
Atracurium injection

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.